Pushing RNA Interference Beyond Liver Diseases and into Diverse Therapeutic Areas |Christopher Richard Anzalone, CEO, Arrowhead Pharmaceuticals Inc. 00:10:00
This conversation delves into the journey of a prominent figure in biotechnology, exploring their transition from private equity to leading a company focused on RNA interference therapies, their strategic approach to revitalizing a struggling business, and the scientific rationale behind expanding RNA interference into various therapeutic areas beyond liver diseases.